fintopic.
Docs Get the API

Hims & Hers expands into unapproved peptides

4 statements from 4 sources, Nov 12, 2026 13:00 UTC to Nov 18, 2026 14:02 UTC
News
Updated
HIMS
Front page

Statements (4)

  1. Neutral

    Hims & Hers launches new peptide treatments including sermorelin, glutathione, NAD+, vitamin B-12, and L-carnitine

    cnbc.com
  2. Neutral

    Hims & Hers launched Peptides+, a new specialty for personalized, proactive health.

    businesswire.com
  3. Neutral

    The HHS committee voted 8-6 to expand access to six unproven peptides including BPC-157, Epitalon, KPV, MOTS-c, Semax, and TB-500.

    fortune.com
  4. Bullish

    Hims stock increased on a Health Department push to legalize six peptides.

    investors.com